Scarica l'app Stockscreener
48.64
0.89%
0.43
Pre-mercato:
48.63
-0.010
-0.02%
Qiagen Nv Borsa (QGEN) Ultime notizie
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - BioSpace
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - MSN
Qiagen and Gencurix partner for oncology tests - MSN
Qiagen’s Voting Rights Notification Highlights BlackRock’s Influence - TipRanks
BlackRock’s Significant Stake in Qiagen Revealed - TipRanks
Qiagen (QGEN) Partners with Gencurix to Enhance Oncology Diagnos - GuruFocus
Qiagen, Gencurix Launch Oncology Testing Development Partnership - MarketScreener
Qiagen and Gencurix partner for oncology tests (QGEN:NYSE) - Seeking Alpha
QIAGEN, GENCURIX announce QIAcuity Digital PCR IVD Assay Development Partnership - marketscreener.com
QGEN Stock Rises in After Market Following Partnership With Incyte - MSN
Qiagen and Incyte announce precision medicine collaboration - BioSpectrum Asia
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Medical Device Network
QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers - MarketScreener
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
QIAGEN and Incyte Announce Precision Medicine Collaboration to D - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) | QGEN Stock News - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Yahoo Finance
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen Announces Significant Shareholding Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Qiagen Reports Change in Voting Rights Held by BlackRock - TipRanks
Qiagen Announces Voting Rights Notification by AFM - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
QIAGEN (QGEN) Partners with Tracer Biotechnologies for MRD Assays - GuruFocus
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QGEN Partners with Tracer Biotechnologies to Advance Cancer Test - GuruFocus
Qiagen (NYSE:QGEN) Sees Large Increase in Short Interest - Defense World
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - marketscreener.com
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QGEN Partners with Tracer Biotechnologies to Advance Cancer Testing | QGEN Stock News - GuruFocus
Qiagen, Tracer Biotechnologies announce strategic partnership - TipRanks
Transcript : Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener
Qiagen N.V. Reports Significant Voting Rights Held by BlackRock - TipRanks
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Here's Why Qiagen (QGEN) is a Strong Value Stock - Yahoo Finance
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances - Yahoo Finance
QIAGEN NV : Receives a Buy rating from Deutsche Bank - marketscreener.com
Qiagen expands portfolio for minimal residual disease testing in oncology - BioSpectrum Asia
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology - marketscreener.com
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma - marketscreener.com
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostic - GuruFocus
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostics | QGEN Stock News - GuruFocus
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
1.52%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):